Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.84 Insider Own30.87% Shs Outstand8.40M Perf Week-6.78%
Market Cap20.84M Forward P/E- EPS next Y-1.42 Insider Trans0.00% Shs Float5.90M Perf Month7.49%
Income-15.42M PEG- EPS next Q-0.57 Inst Own7.05% Short Float1.70% Perf Quarter40.23%
Sales0.00M P/S- EPS this Y-6.83% Inst Trans12.62% Short Ratio1.17 Perf Half Y-9.29%
Book/sh1.44 P/B1.70 EPS next Y27.37% ROA-71.76% Short Interest0.10M Perf Year-12.92%
Cash/sh1.56 P/C1.56 EPS next 5Y- ROE-84.04% 52W Range1.56 - 4.08 Perf YTD38.64%
Dividend Est.- P/FCF- EPS past 5Y56.03% ROI-126.94% 52W High-40.20% Beta1.41
Dividend TTM- Quick Ratio5.05 Sales past 5Y0.00% Gross Margin- 52W Low56.41% ATR (14)0.24
Dividend Ex-Date- Current Ratio5.05 EPS Y/Y TTM-5.91% Oper. Margin0.00% RSI (14)51.26 Volatility8.09% 10.32%
Employees7 Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.01 EPS Q/Q-7.83% Payout- Rel Volume0.05 Prev Close2.36
Sales Surprise- EPS Surprise14.81% Sales Q/Q- EarningsMar 13 BMO Avg Volume85.90K Price2.44
SMA20-1.89% SMA5013.20% SMA20010.12% Trades Volume4,186 Change3.39%
Apr-11-24 07:30AM
Mar-28-24 08:00AM
Mar-25-24 08:30AM
Mar-18-24 08:00AM
Mar-13-24 07:30AM
07:30AM Loading…
Mar-04-24 07:30AM
Feb-15-24 08:00AM
Feb-08-24 08:00AM
Jan-04-24 08:00AM
Nov-06-23 04:01PM
Oct-31-23 09:01AM
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-19-23 08:00AM
08:05AM Loading…
Sep-06-23 08:05AM
Aug-14-23 08:00AM
Aug-10-23 08:45AM
Aug-07-23 08:00AM
Jun-15-23 08:00AM
May-31-23 08:30AM
May-11-23 07:00AM
May-09-23 08:00AM
May-01-23 08:00AM
Apr-24-23 09:00AM
Apr-20-23 04:05PM
Apr-19-23 09:28AM
Apr-17-23 08:00AM
Mar-22-23 08:00AM
08:00AM Loading…
Mar-17-23 08:00AM
Mar-15-23 08:05AM
Mar-13-23 08:05AM
Mar-07-23 08:05AM
Feb-14-23 08:00AM
Feb-07-23 08:05AM
Dec-13-22 07:30AM
Nov-10-22 04:05PM
Oct-18-22 07:00AM
Sep-06-22 09:02AM
Aug-08-22 08:00AM
Jun-09-22 07:00AM
Jun-03-22 07:00AM
May-23-22 08:00AM
May-19-22 07:00AM
May-18-22 04:15PM
May-12-22 08:00AM
May-03-22 12:20PM
Apr-20-22 07:00AM
Mar-23-22 07:00AM
Mar-21-22 07:00AM
Mar-17-22 07:00AM
Mar-07-22 07:00AM
Jan-14-22 09:38AM
Jan-05-22 07:00AM
Jan-03-22 07:00AM
Dec-01-21 08:00AM
Nov-15-21 07:00AM
Nov-04-21 10:51AM
Sep-15-21 07:00AM
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. It engages in the development of a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. The firm created patented treatment methods and associated patented compositions for attenuation and killing of non-pathogenic, Gram-negative bacteria. The company was founded by Michael James Newman on February 24, 2021 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson Glen R.10% OwnerAug 14 '23Buy2.3423,93456,0061,190,400Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 11 '23Buy2.1235,06474,3361,166,466Aug 16 06:01 PM
Anderson Glen R.10% OwnerAug 10 '23Buy1.9444,35486,0471,131,402Aug 16 06:01 PM